Status:
RECRUITING
The Renal Protective Effects of Remote Ischemic Preconditioning in Patients With Chronic Kidney Disease
Lead Sponsor:
Yuanjun Yang
Conditions:
Chronic Kidney Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The incidence of Chronic kidney disease (CKD) is showing an upward trend, but the therapeutic effect of treatment is limited. Remote ischemic conditioning (RIC) has the potential to safeguard remote o...
Detailed Description
Chronic kidney disease (CKD) is characterized by progressive and irreversible loss of nephrons. Currently, due to the increasing prevalence of diabetes, hypertension, obesity, and the impact of popula...
Eligibility Criteria
Inclusion
- CKD Patients with eGFR ≥ 15ml/min/1.73m2
- Age ≥ 18 years old
- 24-hour urine protein excretion ≤ 3.5g
- Subjects who have signed the informed consent form
Exclusion
- Patients with nephrotic syndrome
- Patients with acute kidney injury
- Patients who have undergone renal replacement treatment in the past
- Patients who may have medication changes during RIC or sham-RIC intervention
- Patients with a history of diabetes or glycated hemoglobin \> 8%
- Patients with familial hypercholesterolemia (\>5.5 mmol/L) accompanied by high low-density lipoprotein (\>2.5 mmol/L)
- Patients with contraindications to RIC, such as vascular injury, soft tissue injury, fracture, infection, or known peripheral vascular disease in both arms
- Patients with a history of hemostatic disorders, systemic bleeding, or thrombocytopenia
- Patients with cardiogenic embolism (atrial fibrillation) or other severe arrhythmias (severe bradycardia, third-degree atrioventricular block, or ventricular tachycardia), previous myocardial infarction, or severe heart failure (New York Heart Association Class III and IV)
- Uncontrolled hypertension (defined as systolic blood pressure ≥ 200 mmHg despite antihypertensive treatment)
- Patients with respiratory failure, malignant tumors, or other autoimmune diseases
- Women who are pregnant or breastfeeding at the time of enrollment or any time during the study
Key Trial Info
Start Date :
March 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 30 2027
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT06501222
Start Date
March 1 2024
End Date
March 30 2027
Last Update
August 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
chinese PLA general hospital
Beijing, Beijing Municipality, China, 100853